Condition: Metastatic Colorectal Cancer · Sponsor: The First Affiliated Hospital with Nanjing Medical University
Metastatic colorectal cancer with microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) molecular phenotypes could significantly benefit from immune checkpoint inhibitor therapy, ushering in the MSI era of immunotherapy for colorectal cancer. However, MSI-H/dMMR is present in only 15%-20% of stage II/III and 5% of stage IV colorectal cancer patients, while the vast majority of patients exhibit microsatellite stability (MSS) or proficient mismatch repair (pMMR) types, which are insensitive to immunotherapy. Therefore, how to enhance the efficacy of immunotherapy in the pMMR/MSS population through combination therapy has become a hotspot and challenge in colorectal cancer research.
This description comes directly from the study's public registry record.
Yanhong Gu · +86 25 6830 6714 · guyanhong@njmu.edu.cn
Always discuss trial participation with your own doctor first.
| Jiangsu Province Hospital (The First Affiliated Hospital with Nanjing Medical University) | Nanjing, Jiangsu, China | Recruiting |
| Nanjing First Hospital, Nanjing Medical University Affiliated Hospital | Nanjing, Jiangsu, China | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07718490